OTC Markets EXMKT - Delayed Quote USD

Nexeon Medsystems Inc (NXNN)

Compare
0.0001 0.0000 (0.00%)
At close: October 29 at 4:00 PM EDT
Loading Chart for NXNN
DELL
  • Previous Close 0.0000
  • Open 0.0001
  • Bid --
  • Ask --
  • Day's Range 0.0001 - 0.0001
  • 52 Week Range 0.0001 - 0.0001
  • Volume 265
  • Avg. Volume 0
  • Market Cap (intraday) 78,625
  • Beta (5Y Monthly) 6.27
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.

www.nexeonmedsystems.com

62

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NXNN

View More

Performance Overview: NXNN

Trailing total returns as of 11/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NXNN
0.00%
S&P 500
24.05%

1-Year Return

NXNN
0.00%
S&P 500
31.08%

3-Year Return

NXNN
99.93%
S&P 500
25.77%

5-Year Return

NXNN
100.00%
S&P 500
89.52%

Compare To: NXNN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NXNN

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -16.84%

  • Return on Assets (ttm)

    -19.72%

  • Return on Equity (ttm)

    -17.39%

  • Revenue (ttm)

    9.82M

  • Net Income Avi to Common (ttm)

    -1.65M

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    125.57k

  • Total Debt/Equity (mrq)

    43.78%

  • Levered Free Cash Flow (ttm)

    1.57M

Research Analysis: NXNN

View More

Company Insights: NXNN

Research Reports: NXNN

View More

People Also Watch